drugset / Trial / NCT02027818

Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy

NCT02027818

Phase 2 Completed 20 enrolled Jules Bordet Institute
NaSingle-groupOpen-labelDiagnostic

Summary

We will observe if ICG fluorescence correlates with margins of breast tumours after iv injection of the contrast agent

Timeline

Start
2014-01
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 0.25 mg/kg Intravenous

Indications